Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Although slightly significant differences were observed between the monotherapy and dual therapy groups in the ADC and SCC models, we consider that the combination of the two inhibitors did not have a very potent additive antitumor effect (only 5% and 20% of mice treated with the combination had an ORR < −0.75 in ADCs and SCC, respectively).

also in 1,756 other papers